Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26131114 | 0.86 | ALDH1A1 (0.54) | PTPN2PTPN1ALDH1A1KDM4EACHE | |
| SCHEMBL30496080 | 0.82 | PTPN2 (0.60) | PTPN2PTPN1PTPN6STSALDH1A1 | |
| SCHEMBL7714103 | 0.82 | PTPN2 (0.60) | PTPN2PTPN1PTPN6STSALDH1A1 | |
| SCHEMBL6107606 | 0.80 | STS (0.60) | PTPN2PTPN1PTPN6STSNPC1 | |
| SCHEMBL14447471 | 0.80 | PTPN2 (0.62) | PTPN2PTPN1PTPN6STSNPC1 | |
| SCHEMBL8702500 | 0.79 | PTPN2 (0.54) | PTPN2PTPN1PTPN6STSNPC1 | |
| SCHEMBL25794128 | 0.78 | PTPN2 (0.64) | PTPN2PTPN1PTPN6STSNPC1 | |
| SCHEMBL13060443 | 0.77 | PTPN2 (0.62) | PTPN2PTPN1PTPN6STSNPC1 | |
| SCHEMBL28898378 | 0.77 | PTPN1 (0.90) | PTPN2PTPN1PTPN6STSNPC1 | |
| SCHEMBL3181308 | 0.77 | PTPN2 (0.62) | PTPN2PTPN1PTPN6STSNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-17 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3575288-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3575288-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676460-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3575288-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-12-04 | — | — | EP | disclosed |
| US-9458114-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575184-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575184-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTON-MYERS SQUIBB COMPANY (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTON-MYERS SQUIBB COMPANY (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2473487-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028741-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028741-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | PTPN2 3282/4885PTPN1 2647/4885PTPN6 2703/4885 |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | PTPN2 3282/4885PTPN1 2647/4885PTPN6 2703/4885 |
| US-10676460-B2 | Quinazolines as potassium ion channel inhibitors | KCNJ4, KCNK4, KCNQ4 | PTPN2 3282/4885PTPN1 2647/4885PTPN6 2703/4885 |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | PTPN2 3282/4885PTPN1 2647/4885PTPN6 2703/4885 |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNH3, KCNQ4 | PTPN2 3634/4885PTPN1 3162/4885PTPN6 3172/4885 |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | KCNJ4, KCNK4, KCNQ4 | PTPN2 3282/4885PTPN1 2647/4885PTPN6 2703/4885 |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | PTPN2 3282/4885PTPN1 2647/4885PTPN6 2703/4885 |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | PTPN2 3282/4885PTPN1 2647/4885PTPN6 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.